Outlook for Holdings Have Worsened; ARKG in MicroQuad3
We refreshed the weighted estimate MicroQuad trend for the Ark Genomic Revolution ETF (ARKG) based on the most recent data. The current trend continue to slow from the February 2021 peak, but the outlook has shifted from a mid-2021 reacceleration to a later time point sometime in 2022. Like many other names in our space, ARKG bottomed around June and July of 2020, then rallied in the second half. That momentum looks to have faded. Much of the change appears tied to their nearly 7% position in Teladoc (TDOC), but there are similar trends throughout the holdings.
We will keep an eye on this one but will need to see significant improvement in the near-term outlook before move on.
All data available upon request. Please reach out to with any inquiries.
Thomas Tobin
Managing Director
Twitter
LinkedIn
